Arietis Corporation
Boston, MA
- UEI
- DCSGCN3N8D87
- CAGE
- 4GT84
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 650 Albany St, Boston, MA 02118, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| ST Jude Children's Research Hospital Inc. | R01CA264837 | $333,366 | |
| ST Jude Children's Research Hospital Inc. | R01AI170765 | $390,000 | |
| ST Jude Children's Research Hospital Inc. | R01AI180231 | $694,106 | |
| ST Jude Children's Research Hospital Inc. | R01AI170765 | $390,000 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Curza Inc. | Salt Lake City, UT | — |
| Entasis Therapeutics, Inc. | Waltham, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Fimbrion Therapeutics Inc. | St. Louis, MO | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Crestone, Inc. | Boulder, CO | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Basilea Pharmaceutica International Ltd, Allschwil | Allschwil, BL | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Arietis Corporation, doing business as Arietis Corp, is a corporate entity registered to receive federal contract and grant awards since 2006. It is a for-profit organization that develops novel antibiotics and antimicrobial therapies.
Arietis Corp has received two major federal grant awards from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). The first award for $1.0M aims to develop a new ureadepsipeptide antibiotic called 5192 to treat infections caused by drug-resistant gram-positive pathogens like MRSA, VRE, and drug-resistant Streptococcus pneumoniae. This antibiotic has a unique mechanism that enables it to kill non-growing and dormant bacterial cells, addressing biofilm-related infections. The second award for $7.9M focuses on developing a new class of urea-depsipeptide antibiotics to treat prosthetic joint infections caused by Staphylococcus aureus and epidermidis, including multi-drug resistant strains. These antibiotics kill bacteria by activating the ClpP protease, causing cells to self-digest, and have the potential to minimize surgical interventions. Arietis Corp has also been a sub-grantee for a project at St. Jude Children's Research Hospital Inc., working on targeting NuoD for the treatment of H. pylori infections.
Quick answers
Is Arietis Corporation registered in SAM.gov?
Yes. Arietis Corporation's SAM.gov registration is active through April 6, 2027.
What is Arietis Corporation's most recent federal award?
Arietis Corporation's most recent federal grant award is Development of a dual-targeting clpp activating antibiotic - the world health organization has declared that… (R44AI179382), from National Institute of Allergy and Infectious Diseases (NIH), on September 1, 2023.
On GovTribe
See Arietis Corporation's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors